ISAL 2019 | Precision medicine in hematological oncology: development to the present day
Tariq Mughal, MD, MB, BS, MRCS, MRCP, FRCP, of Tufts University School of Medicine, Boston, MA, gives us a comprehensive background of the devlopment of precision medicine in the field of hematological oncology. Starting with the case of imatinib in chronic myeloid leukemia (CML), he takes us through to the present day. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up